Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Gabamide - Wikipedia
Gabamide - Wikipedia
From Wikipedia, the free encyclopedia

Pharmaceutical compound
Gabamide
Clinical data
Other namesGABAmide; GABAMIDE; GABA amide; 4-Aminobutanamide; 4-ABAD; 4-Aminobutyramide; gamma-Aminobutyramide; γ-Aminobutyramide; GABAD; gamma-Aminobutyric acid amide; γ-Aminobutyric acid amide
Drug classGABA receptor agonist
ATC code
  • None
Identifiers
IUPAC name
  • 4-aminobutanamide
CAS Number
  • 3251-08-9
PubChem CID
  • 18615
ChemSpider
  • 17581
UNII
  • DQN3YXP96S
ChEMBL
  • ChEMBL1199935
CompTox Dashboard (EPA)
  • DTXSID80186235 Edit this at Wikidata
ECHA InfoCard100.019.852 Edit this at Wikidata
Chemical and physical data
FormulaC4H10N2O
Molar mass102.137 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • C(CC(=O)N)CN
InChI
  • InChI=1S/C4H10N2O/c5-3-1-2-4(6)7/h1-3,5H2,(H2,6,7)
  • Key:WCVPFJVXEXJFLB-UHFFFAOYSA-N

Gabamide, or GABAmide, also known as γ-aminobutyramide (GABAD), is a GABA receptor agonist and GABA analogue, or more specifically the amide of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).[1][2] Along with GABA and progabide acid (SL-75.102), gabamide is an active metabolite of the anticonvulsant drug progabide (Gabrene; SL-76.002).[1][2] Unlike progabide, but similarly to GABA, gabamide is unable to cross the blood–brain barrier and hence is peripherally selective.[2] However, gabamide and GABA are formed in the brain from progabide following its entry into this part of the body.[2]

See also

[edit]
  • γ-Amino-β-hydroxybutyric acid (GABOB)
  • γ-Hydroxybutyrate (GHB)

References

[edit]
  1. ^ a b Bartholini G (1981). "Present Knowledge of GABA Receptor Agonists". Medicinal Chemistry Advances. Elsevier. pp. 345–353. doi:10.1016/b978-0-08-025297-1.50032-5. ISBN 978-0-08-025297-1. Retrieved 6 October 2025.
  2. ^ a b c d Bergmann KJ (1985). "Progabide: a new GABA-mimetic agent in clinical use". Clinical Neuropharmacology. 8 (1): 13–26. doi:10.1097/00002826-198503000-00002. PMID 2983890. Progabide, a new synthetic compound defined as the Schiff base of gamma-aminobutyramide and a substituted benzophenone, has been developed. Well absorbed, and relatively free of toxicity, it is both a direct GABA receptor agonist as well as an exogenous source of GABA. [...]
  • v
  • t
  • e
GABA receptor modulators
Ionotropic
GABAATooltip γ-Aminobutyric acid A receptor
  • Agonists: 4-AHP
  • (+)-Catechin
  • Bamaluzole
  • Barbiturates (e.g., phenobarbital)
  • Beta-Alanine
  • BL-1020
  • DAVA
  • DH-P4S
  • Dihydromuscimol
  • GABA
  • Gabamide
  • GABOB
  • Gaboxadol (THIP)
  • Homotaurine (tramiprosate, 3-APS)
  • IAA (IMA)
  • Ibotenic acid
  • iso-THAZ
  • Isoguvacine
  • Isonipecotic acid
  • Kojic amine
  • L-838,417
  • Lignans (e.g., honokiol)
  • Methylglyoxal
  • Monastrol
  • Muscimol
  • Nefiracetam
  • Neuroactive steroids (e.g., allopregnanolone)
  • Org 20599
  • PF-6372865
  • Phenibut
  • Picamilon
  • 4-PIOL
  • P4S
  • Progabide
  • Propofol
  • Quisqualamine
  • SL-75102
  • Taurine
  • TACA
  • TAMP
  • Terpenoids (e.g., borneol)
  • Thio-4-PIOL
  • Thiomuscimol
  • Tolgabide
  • ZAPA
  • Positive modulators (abridged; see here for a full list): α-EMTBL
  • Alcohols (e.g., drinking alcohol, 2M2B)
  • Anabolic steroids
  • Avermectins (e.g., ivermectin)
  • Barbiturates (e.g., phenobarbital)
  • Benzodiazepines (e.g., diazepam)
  • Bromide compounds (e.g., potassium bromide)
  • Carbamates (e.g., meprobamate)
  • Carbamazepine
  • Chloralose
  • Chlormezanone
  • Clomethiazole
  • Dihydroergolines (e.g., ergoloid (dihydroergotoxine))
  • Etazepine
  • Etifoxine
  • Fenamates (e.g., mefenamic acid)
  • Flavonoids (e.g., apigenin, hispidulin)
  • Fluoxetine
  • Flupirtine
  • Imidazoles (e.g., etomidate)
  • Kava constituents (e.g., kavain)
  • Lanthanum
  • Loreclezole
  • Monastrol
  • Neuroactive steroids (e.g., allopregnanolone, cholesterol, THDOC)
  • Niacin
  • Niacinamide
  • Nonbenzodiazepines (e.g., β-carbolines (e.g., abecarnil), cyclopyrrolones (e.g., zopiclone), imidazopyridines (e.g., zolpidem), pyrazolopyrimidines (e.g., zaleplon))
  • Norfluoxetine
  • Petrichloral
  • Phenols (e.g., propofol)
  • Phenytoin
  • Piperidinediones (e.g., glutethimide)
  • Propanidid
  • Pyrazolopyridines (e.g., etazolate)
  • Quinazolinones (e.g., methaqualone)
  • Retigabine (ezogabine)
  • ROD-188
  • Skullcap constituents (e.g., baicalin)
  • Stiripentol
  • Sulfonylalkanes (e.g., sulfonmethane (sulfonal))
  • Topiramate
  • Valerian constituents (e.g., valerenic acid)
  • Volatiles/gases (e.g., chloral hydrate, chloroform, diethyl ether, paraldehyde, sevoflurane)
  • Antagonists: Bicuculline
  • Coriamyrtin
  • Dihydrosecurinine
  • Famiraprinium
  • Gabazine (SR-95531)
  • Hydrastine
  • Hyenanchin (mellitoxin)
  • Iso-THIP
  • PHP-501
  • Pitrazepin
  • Securinine
  • Sinomenine
  • SR-42641
  • THAZ
  • Thio-4-PIOL
  • Thio-THIP
  • Thiocolchicoside
  • Tutin
  • Negative modulators: 1,3M1B
  • 3M2B
  • 11-Ketoprogesterone
  • 17-Phenylandrostenol
  • α3IA
  • α5IA (LS-193,268)
  • β-CCB
  • β-CCE
  • β-CCM
  • β-CCP
  • β-EMGBL
  • Anabolic steroids
  • Amiloride
  • Anisatin
  • β-Lactams (e.g., penicillins, cephalosporins, carbapenems)
  • Basmisanil
  • Bemegride
  • Bicyclic phosphates (TBPS, TBPO, IPTBO)
  • BIDN
  • Bilobalide
  • Bupleurotoxin
  • Bupropion
  • CHEB
  • Chlorophenylsilatrane
  • Cicutoxin
  • Cloflubicyne
  • Cyclothiazide
  • DHEA
  • DHEA-S
  • Dieldrin
  • (+)-DMBB
  • DMCM
  • DMPC
  • EBOB
  • Etbicyphat
  • FG-7142 (ZK-31906)
  • Fiproles (e.g., fipronil)
  • Flavonoids (e.g., amentoflavone, oroxylin A)
  • Flumazenil
  • Fluoroquinolones (e.g., ciprofloxacin)
  • Flurothyl
  • Furosemide
  • Golexanolone
  • Iomazenil (123I)
  • IPTBO
  • Isopregnanolone (sepranolone)
  • L-655,708
  • Laudanosine
  • Lindane
  • MaxiPost
  • Morphine
  • Morphine-3-glucuronide
  • MRK-016
  • Naloxone
  • Naltrexone
  • Nicardipine
  • Nonsteroidal antiandrogens (e.g., apalutamide, bicalutamide, enzalutamide, flutamide, nilutamide)
  • Oenanthotoxin
  • Pentylenetetrazol (pentetrazol)
  • Phenylsilatrane
  • Picrotoxin (i.e., picrotin, picrotoxinin and dihydropicrotoxinin)
  • PNV-001
  • Pregnenolone sulfate
  • Propybicyphat
  • PWZ-029
  • Radequinil
  • Ro 15-4513
  • Ro 19-4603
  • RO4882224
  • RO4938581
  • Sarmazenil
  • SCS
  • Suritozole
  • TB-21007
  • TBOB
  • TBPS
  • TCS-1105
  • Terbequinil
  • TETS
  • Thujone
  • U-93631
  • Zinc
  • ZK-93426
GABAA-ρTooltip γ-Aminobutyric acid A-rho receptor
  • Agonists: BL-1020
  • CACA
  • CAMP
  • Homohypotaurine
  • GABA
  • GABOB
  • Ibotenic acid
  • Isoguvacine
  • Muscimol
  • N4-Chloroacetylcytosine arabinoside
  • Picamilon
  • Progabide
  • TACA
  • TAMP
  • Thiomuscimol
  • Tolgabide
  • Positive modulators: Allopregnanolone
  • Alphaxolone
  • ATHDOC
  • Lanthanides
  • Antagonists: (S)-2-MeGABA
  • (S)-4-ACPBPA
  • (S)-4-ACPCA
  • 2-MeTACA
  • 3-APMPA
  • 4-ACPAM
  • 4-GBA
  • cis-3-ACPBPA
  • Aza-THIP
  • CGP-36742 (SGS-742)
  • DAVA
  • Gabazine (SR-95531)
  • Gaboxadol (THIP)
  • I4AA
  • Iso-THIP
  • Isonipecotic acid
  • Loreclezole
  • P4MPA
  • P4S
  • SKF-97541
  • SR-95318
  • SR-95813
  • THAZ
  • Thio-THIP
  • TPMPA
  • trans-3-ACPBPA
  • ZAPA
  • Negative modulators: 5α-Dihydroprogesterone
  • Bilobalide
  • Loreclezole
  • Picrotoxin (picrotin, picrotoxinin)
  • Pregnanolone
  • ROD-188
  • THDOC
  • Zinc
Metabotropic
GABABTooltip γ-Aminobutyric acid B receptor
  • Agonists: 1,4-Butanediol
  • 3-APPA
  • 4-Fluorophenibut
  • Aceburic acid
  • Arbaclofen
  • Arbaclofen placarbil
  • Baclofen
  • BL-1020
  • GABA
  • Gabamide
  • GABOB
  • GBL
  • GHB
  • GHBAL
  • GHV
  • GVL
  • Isovaline
  • JZP-386
  • Lesogaberan
  • Phenibut
  • Picamilon
  • Progabide
  • Sodium oxybate
  • SKF-97,541
  • SL 75102
  • Tolgabide
  • Tolibut
  • Valiloxybate (XW-10172)
  • Positive modulators: ADX-71441
  • ASP-8062
  • BHF-177
  • BHFF
  • rac-BHFF
  • BSPP
  • CGP-7930
  • CGP-13501
  • GS-39783
  • INDV-1000
  • KK-92A
  • Antagonists: 2-Hydroxysaclofen
  • CGP-35348
  • CGP-36742
  • CGP-46381
  • CGP-52432
  • CGP-54626
  • CGP-55845
  • CGP-64213
  • DAVA
  • Homotaurine (tramiprosate, 3-APS)
  • Phaclofen
  • Saclofen
  • SCH-50911
  • Negative modulators: Compound 14
See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Gabamide&oldid=1328700051"
Categories:
  • Drugs not assigned an ATC code
  • Amides
  • GABA analogues
  • GABA receptor agonists
  • Human drug metabolites
  • Peripherally selective drugs
  • Nervous system drug stubs
Hidden categories:
  • Articles with short description
  • Short description is different from Wikidata
  • ECHA InfoCard ID from Wikidata
  • Chemical pages without DrugBank identifier
  • Articles without KEGG source
  • Drugs with no legal status
  • Articles containing unverified chemical infoboxes
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id